A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

NCT06620848 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: HRS-4642 monotherapy
DRUG: HRS-4642 and adebrelimab combination therapy

Sponsor

Shanghai Zhongshan Hospital